1Berhanu P,Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycemic control, insulin dose requirement and lipid profile with type 2 diabetes previously poorly controlled with ombination therapy. Diabetes Obes Metab, 2007. 9 : 512-520.
2Wan J,Xiong S, Chao S, et al. PPAR3, gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol, 2010, 9 : 13.
3Moffett SP, Feingold E, Barmada MM, et al. The C161-T polymorphism in peroxisome proliferator-activated receptor gamma, but not P12A, is associated with insulin resistance in Hispanic and non-Hispanic white women: evidence for another functional variant in peroxisome proliferator-activated receptor gamma. Metabolism, 2005, 54: 1552-1556.
4SchafflerA, Barth N, Schmitz G, et al. Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort. Endocrine, 2001, 14 : 369-373.
5Tan M, Johns D, Gonzalez GOlvez G, et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a muhicenter, randomized, double-blind, parallel-group trial. Clin Ther, 2004, 26: 680-693.
6Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev, 1998, 14 : 263-283.
7Lim S,Jin CJ, Kim M, et al. PPARγ gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol, 2006, 26: 808-813.
8Halabi CM, Beyer AM, de Lange WJ, et al. Interference with PPARγ function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab, 2008, 7: 215-226.
9Gizard F, Bruemmer D. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator- activated receptor-γ: Therapeutic implications for cardiovascular diseases. PPAR Res, 2008, 2008 : 429123.
10Meredith D, Panchatcharam M, Miriyala S, et al. Dominant- negative loss of PPARγ function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioseler Thromb Vasc Biol, 2009, 29: 465-471.
